Search PubMed⌕ Search

Biomedical subjects

M Okabe

Publications and source records attributed to M Okabe.

At least 379 records · Page 21Linked to original sources
PubMed1987

Immunological functions and T-cell receptor gene rearrangement of proliferating lymphocytes in a case of T gamma lymphocytosis with neutropenia.

A case of T gamma lymphocytosis with neutropenia is presented. The patient showed mild lymphocytosis, splenomegaly, anemia, neutropenia and recurrent infections without progression for 15 years. The expanded lymphoid cells were morphologically large granular lymphocytes (LGL), had receptors for both sheep red blood cells and IgG-Fc portion and were positive for OKT3 and 8 antigens. They displayed ADCC activity, whereas they showed low responses to T-cell mitogens and deficient NK activity. They showed neither suppressor activity on antibody production by B-cells nor suppressor activity on CFU-C formation. The DNA isolated from the expanded cells of the patient showed T-cell beta-chain (T beta) gene rearrangement, indicating monoclonality of the proliferation. This finding supports that the proliferation of T8 lymphocytes in the present case is neoplastic rather than reactive, regardless of the benign clinical course.

Adult↗
PubMed1987

Non-T, non-B acute lymphocytic leukemias: cellular origin based on molecular analyses of immunoglobulin and T-cell alpha- and beta-chain receptor gene rearrangements.

Fifteen non-T, non-B acute lymphocytic leukemia (ALL) cases were investigated for determining cellular origin based on molecular (immunoglobulin and T-cell alpha-receptor (TcR alpha) and T-cell beta-receptor (TcR beta) genes) and immunophenotypical analyses. As defined by monoclonal antibodies, they were classified into 2 groups; 12 cases as common ALL antigen (CALLA)-positive ALL and 3 cases as CALLA-negative ALL. Southern blot analysis revealed that 11 CALLA-positive ALL cases contained rearranged JH gene and 2 of them contained rearranged Jx genes, similar to recent views that most CALLA-positive leukemic cells are neoplastic B-cell precursors. One CALLA-positive ALL case, whose leukemic cells were also Leu-1 positive, showed no rearrangement of JH and TcR beta genes. On the other hand, non-T, non-B CALLA-negative ALL, so called null ALL, consisted of heterogenous groups with regard to lymphocyte differentiation and lineage; one out of 3 null ALL cases may be truely undifferentiated as shown neither JH nor TcR beta gene rearrangement, but other 2 cases showed either JH or TcR beta gene rearrangement. Dual rearrangements of Ig and TcR beta genes occur frequently in 3 out of 15 non-T, non-B ALL cases, but all cases of bigenotype showed no doubly marked profile and retained a completely fidelous immunophenotypic pattern. We further investigated the possibility that analysis of TcR alpha gene may be useful for determining cellular origin of non-T, non-B ALL leukemic cells.

Genotype↗
PubMed1987

Cloning of granulocyte colony-stimulating factor cDNA from human macrophages and its expression in Escherichia coli.

Human granulocyte colony-stimulating factor (hG-CSF) cDNA was cloned, by using a synthetic oligonucleotide probe, from an Okayama-Berg cDNA library of lipopolysaccharide-stimulated human peripheral blood macrophages. The cDNA encodes a polypeptide with an amino acid sequence which completely matches that of the known polypeptide with hG-CSF activity derived from human tumor cell lines. Expression in E. coli of high levels of the protein (about 10% of total cellular proteins) was accomplished under control of the trp promoter, and the purified protein was proved to have hG-CSF activity. Our data provide evidence that human peripheral blood macrophages do produce hG-CSF mRNA when stimulated exogenously, suggesting they are the producer of naturally occurring hG-CSF.

Base Sequence↗
PubMed1987

Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.

A new Philadelphia chromosome (Ph1)-positive cell line, designated TOM-1, was derived from bone marrow cells of a patient with Ph1-positive acute lymphocytic leukemia (ALL). The TOM-1 cells were positive for Ia and B1 antigens and terminal deoxynucleotidyl transferase (TdT) but negative for common ALL antigen. Although neither surface Ig nor cytoplasmic Ig was detected, the TOM-1 cells contained rearranged immunoglobulin-H chain genes but retained germ-line kappa chain and germ-line T cell receptor beta-chain genes. These results indicate that the TOM-1 cells reside as the progenitor of pre-B cells. We have investigated the chromosome 22 breakpoint and c-abl gene expression in the TOM-1 cells. We found that the breakpoint on chromosome 22 was within the breakpoint cluster region (bcr) in the TOM-1 cells. We also found the breakpoints within or near bcr in four of six Ph1-positive ALL cases, similar to the findings in Ph1-positive CML cases. Amplification of the c-abl gene was not detected in the TOM-1 cells. The leukemic cells isolated from a patient with CML in myeloid crisis contained a novel 8-kilobase (kb) abl-related messenger RNA (mRNA), but the TOM-1 cells contained c-abl transcripts of only normal sizes, despite the fact that they showed the bcr gene rearrangement.

Antigens, Differentiation, B-Lymphocyte↗
PubMed1987

[Study on serum TSH and its response to TRH measured by a high sensitive immunoradiometric assay during and after pregnancy].

With a new highly sensitive immunoradiometric assay (IRMA), serum thyrotropin (TSH) concentrations were determined in 213 healthy pregnant women. Serum free thyroxine (FT4) and human chorionic gonadotropin (HCG) levels were also measured in the same individuals. The mean serum TSH value in the 1st trimester was 0.8 microU/ml and significantly lower than those of the other three periods and non-pregnant women. Seventeen of 77 (22.1%) and 2 of 128 (1.6%) subjects in the 1st and 3rd trimester, respectively, had an undetectable serum TSH value (less than 0.1 microU/ml) with normal or slightly elevated serum FT4 levels and these pregnant women had no clinical signs or symptoms of thyrotoxicosis. Significant positive correlations were found between serum FT4 and HCG in the 1st and 3rd trimester. In 13 subjects whose serum basal TSH values had been less than 0.1 microU/ml, the thyrotropin-releasing hormone (TRH) stimulation test was performed. Two of 4 subjects in the 1st trimester and one of 8 subjects in the 2nd trimester did not respond to TRH and their serum TSH values before TRH administration were less than 0.1 microU/ml. Although the exact mechanism of blunted TSH response to TRH is not clear, the feedback suppression of serum TSH by slightly elevated serum FT4 concentrations may occur early in pregnancy. However, in the 3rd trimester serum FT4 values fell below the reference range without an elevation of serum TSH. Other factors regulating the secretion of TSH during pregnancy can be postulated.

Female↗
PubMed1987

[Clinical analysis of 82 patients with non-Hodgkin's lymphoma--mainly on the evaluation of therapeutic efficacy].

UNLABELLED: A retrospective study of eighty-two patients with non-Hodgkin's lymphoma whom we had treated for the past ten years was performed to discuss the prognosis (50% survival duration (50%s) and 5-year survival rate (5ys)) of the histopathological types, clinical stages and therapeutic regimens respectively. Patients were staged according to the Ann Arbor criteria and classified histopathologically according to the Lymphoma Study Group (LSG) and new Working Formulation. The treatment programs consisted of radiotherapy alone (Co alone), VEP regimen (vincristine, cyclophosphamdde and prednisolone), VEPA regimen (VEF + adriamycin) and radiotherapy followed by adjuvant chemotherapy (co + chemotherapy). Survival curve was calculated by the method of Kaplan and Meier. Camparisons in remission duration and survival were analyzed by the Logrank test. RESULTS: 1. In 82 evaluable patients, 50%s was 27 months and 5ys was 31%. For patients with complete remission (CR), partial remission (PR) and no response (NR) 50%s was 49, 6 and 4 months respectively (CR vs. PR: p less than 0.01). 2. For the several histopathological types 50%s was the following: d-medium (6 months) less than lymphoblastic (17 months) less than d-large (27 months) less than d-small (32 months) less than pleomorphic (43 months). There was difference in 50%s and 5ys for three grade malignancies classified by new Working Formulation (p greater than 0.10). 3. For clinical stages (Cs) 50%s was the following: Cs I; 40 months, Cs II: 49 months, Cs III: 43 months and Cs IV: 6 months respectively. There was no difference in its duration in Cs I, II and III (p less than 0.10). However, in 5ys Cs I was superior to Cs II, III and IV in order (Cs III vs. Cs IV: p less than 0.01). 4. For initial therapy the prognosis was better with VEPA regimen (50%s: 49 months, 5ys: 39%) than with VEP regimen (50%s: 24 months, 5ys: 24%) (p greater than 0.10), and with Co + chemotherapy (50%s: 54 months, 5ys: 30%) than with Co alone (50%s: 18 months, 5ys: 25%) (p greater than 0.10). 5. For localized lymphoma (Cs I, II) the prognosis was better with VEP regimen (50%s) 80 motnths, 5ys: 62%) than with Co alone (50%s: 32 months, 5ys: 27%) (p greater than 0.10), and the remission duration was significantly longer with VEP regimen than with Co alone (p less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)

Adolescent↗